2016 meeting time, together with a subsequent drafting group meeting in July, was spent on JCGM 103: *Supplement 3 to the Guide to the Expression of Uncertainty in Measurement*. This new guidance document deals with the development and use of measurement models. In addition to setting out the general structure of possible measurement models, the supplement covers a variety of mathematical aspects that are useful in metrology. Example topics include model choice for numerical stability, model parametrization, dealing with implicit measurement models (in which the result cannot be simply written as a function of input variables), and the use of transformations to simplify models or improve the accuracy of computation. A draft of this new Guide is in the late stage of completion and anticipated in early 2017.

## References


1. JCGM 100:201X Committee Draft—Evaluation of measurement data—Guide to uncertainty in measurement, Issued to member bodies December 2014
2. W. Bich, Revision of the 'Guide to the Expression of Uncertainty in Measurement'. Why and how. *Metrologia* **51**:S155–S158 (2014)
3. W. Bich *et al.* Towards a new GUM—an update. *Metrologia* **53**:S149-S159 (2016)


**For more information, please contact Juris Meija <Juris.Meija@nrc-cnrc.gc.ca>. Dr. Meija is a Titular Member of the IUPAC Interdivisional Committee for Terminology, Nomenclature and Symbols, Chair of the IUPAC Commission on Isotopic Abundances and Atomic Weights, and IUPAC representative on JCGM-WG1.**

# Bookworm

Books and publications hot off the press.
See also www.iupac.org/what-we-do

## Successful Drug Discovery

**János Fischer and Wayne E. Childers (Eds)**
**Wiley-VCH, 2016, ISBN: 978-3-527-34115-3**




The goal of this book series is to help experts in drug research and development, both in academia and industry, with case histories described by their key inventors or by recognized experts whose contributions can also serve as teaching examples.

Published in December 2016, Volume 2 retains the successful approach found in the previous volume: inventors and primary developers of drugs that made it to market tell the story of the drug's discovery and development and relate the often twisted route from the first candidate molecule to the final marketed drug. Eleven selected case studies describe recently introduced drugs that have not been previously covered in textbooks or general references. These range across six different therapeutic fields and provide a representative cross-section of current drug development efforts. Sections include:

I. HDAC Inhibitor Anticancer Drug Discovery
II. Steroidal CYP17 Inhibitor Anticancer Drug Discovery
III. Anti-infective Drug Discoveries
IV. Central nervous system (CNS) Drug Discovery
V. Antiulcer Drug Discovery
VI. Cross Therapeutic Drug Discovery (Respiratory Diseases/Anticancer)

2016 marked the 10th anniversary of the approval of vorinostat, the first marketed histone deacetylase (HDCA) inhibitor. This event inaugurated a stream of HDAC inhibitor approvals and confirmed the validity of this drug target and of epigenetic modulation as a viable therapeutic mechanism. To celebrate this important milestone, *Successful Drug Discovery* presents a number of HDAC inhibitor drug discovery stories.

Backed by copious data and chemical information, the insight and experience of the contributors makes this volume one of the most useful training manuals that a junior medicinal chemist can hope to find. The book is the outcome of an IUPAC project.

See detailed Table of Contents on wiley.com.

**www.wiley.com/WileyCDA/WileyTitle/productCd-3527341153.html**
**www.iupac.org/project/2015-026-1-700**